Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,118Revenue $M2.6Net Margin (%)0Z-Score68.2
Enterprise Value $M986EPS $-0.6Operating Margin %0F-Score4
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yY
Price/Book8.910-y EBITDA Growth Rate %-37.3Quick Ratio14.5Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-6.5Current Ratio14.5Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-36.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-38.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M97.8ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with ACHN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ACHNJean-Marie Eveillard 2014-03-31 Sold Out -0.01%$3.08 - $4.2
($3.5)
$ 11.43227%Sold Out0
ACHNJean-Marie Eveillard 2013-12-31 Buy 0.01%$2.43 - $3.46
($2.9)
$ 11.43294%New holding, 600000 sh.600,000
ACHNJohn Burbank 2012-12-31 Sold Out -0.24%$7.2 - $11.1
($8.86)
$ 11.4329%Sold Out0
ACHNJohn Burbank 2012-09-30 Buy 0.24%$5.61 - $10.41
($7.06)
$ 11.4362%New holding, 500000 sh.500,000
ACHNGeorge Soros 2012-06-30 Sold Out -0.04%$5.94 - $10.95
($7.34)
$ 11.4356%Sold Out0
ACHNGeorge Soros 2012-03-31 Reduce-0.09%$7.71 - $12.375
($9.57)
$ 11.4319%Reduce -50%250,000
ACHNGeorge Soros 2011-12-31 Add0.16%$4.01 - $8
($6.15)
$ 11.4386%Add 2132.14%500,000
ACHNGeorge Soros 2011-09-30 Buy $4.63 - $8.31
($6.37)
$ 11.4379%New holding, 22400 sh.22,400
ACHNDavid Swensen 2007-12-31 Sold Out -0.06%$4.29 - $5.46
($4.9)
$ 11.43133%Sold Out0
ACHNDavid Swensen 2007-06-30 Buy 0.07%$5.02 - $6.16
($5.6)
$ 11.43104%New holding, 39955 sh.39,955
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ACHN is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


ACHN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
RA CAPITAL MANAGEMENT, LLC 2014-09-30Sell1,332,014$10.27.55 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-26Sell2,372,915$11.17-1.79 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-23Sell2,595,071$11.29-2.83 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-11Sell1,704,362$12.45-11.89 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-11Sell1,704,362$20356.3-99.95 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-02Sell835,293$11.63-5.67 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-08-27Sell2,711,352$11.33-3.18 view
Truitt JosephEVP, Chief Commercial Officer 2014-08-25Sell25,000$10.821.39 view
Deshpande MilindPresident and CEO 2014-08-18Sell216,624$109.7 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-08-18Sell4,235,000$9.5315.11 view

Press Releases about ACHN :

    Quarterly/Annual Reports about ACHN:

    News about ACHN:

    Articles On GuruFocus.com
    Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
    Top 4 Insider Buys of Last Week Jun 10 2013 
    comment on ACHN Mar 15 2013 
    comment on ACHN Mar 09 2013 
    Achillion Will Surge If New Drug Is Successful Apr 21 2012 
    Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
    Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 
    Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 27 2010 
    Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 13 2010 
    Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 03 2009 

    More From Other Websites
    Achillion Pharmaceuticals, Inc. Shares Trading At Highs Following Positive Comments From FBR Capital Oct 08 2014
    Achillion to Present Updated Clinical HCV Data on ACH-3102 and Preclinical Profile of ACH-3422 at... Oct 08 2014
    ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Oct 06 2014
    Top 5 Biotech Stocks Over The Past Year Oct 06 2014
    Another volatile session for major averages Sep 30 2014
    What Johnson & Johnson's Alios Acquisition Means for Gilead Sciences Sep 30 2014
    Momentum Stocks Showing Weakness Sep 15 2014
    Biotech targets: Cramer's quality candidates Sep 11 2014
    [video] Cramer: ACAD and ISIS have room to run Sep 11 2014
    Can the Rally in Achillion (ACHN) Shares Continue? Sep 10 2014
    Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte Sep 05 2014
    Why Achillion Pharmaceuticals (ACHN) Stock Might be a Great Pick Sep 05 2014
    5 stocks to watch Sep 03 2014
    Like Volatility? Trade These Four Stocks Sep 03 2014
    Lightning Round: AT&T, Las Vegas Sands & more Sep 02 2014
    No, the Biotech Rally Isn't Over Sep 02 2014
    Morning Movers: Dollar General Ups Bid for Family Dollar; Staples Gains on Upgrade Sep 02 2014
    4 Biotechs That Might Be Bought Soon Aug 29 2014
    Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As Aug 27 2014
    The Zacks Analyst Blog Highlights: Roche, InterMune, Achillion Pharmaceuticals, Puma Biotechnology... Aug 27 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK